Moderna reaffirms 2025-26 guidance, eyes multiple vaccine, oncology, and rare disease launches

Moderna reiterated 2025 revenue guidance of $1.6–$2.0 billion and expects Q4 global Covid sales of $300–$700 million (including $100–$400 million in the US) driven by mNEXSPIKE, Spikevax and mRESVIA. Management projects GAAP expenses to fall to $4.9 billion in 2026 (from $5.3 billion in 2025) and $4.2–$4.6 billion by 2027 with a targeted ~10% gross-margin improvement over three years, while cash is expected to decline to $4.5–$5.0 billion in 2026 (excluding a $600 million drawdown) and reach cash breakeven by 2028. The company is expanding its respiratory franchise to potentially six products by 2028 and flagged key clinical readouts and registrational data in 2026 for oncology (mRNA-4157 with Merck) and rare-disease programs (mRNA-3927, mRNA-3705) ahead of anticipated 2028 launches; Jefferies maintains a Hold and $30 price target.

Analysis

Market structure: Moderna (MRNA) remains a near-term Covid cash engine (Q4 global $300–700M, US $100–400M) and is positioned to capture elderly share (mNEXSPIKE ~33% of 65+). Winners include CDMOs, Merck (MRK) on co-development success, and specialty rare-disease rare-drug economics; losers are incumbent seasonal-vaccine makers (SNY, GSK) facing potential share erosion and pricing pressure. Cross-asset: MRNA equity moves will drive biotech implied vol spikes around readouts; modest debt drawdown ($600M) raises short-term credit sensitivity but limited systemic bond impact.

Risk assessment: Tail risks include regulatory failures (oncology/rare disease), manufacturing bottlenecks that reverse the planned 10% gross-margin gain, or an equity raise if cash falls below ~$4.5B. Immediate (days) risk: sentiment swings on guidance cadence; short-term (weeks–months): Phase IIb melanoma readout early 2026 and registrational rare-disease data in 2026; long-term (2027–28): commercial launches and margin realization. Hidden dependency: commercial uptake hinged on payor acceptance for high-priced rare-disease and combo vaccines.

Trade implications: Favor a calibrated, event-driven exposure—buy-dated optionality into clinical catalysts while hedging near-term downside. Consider dollar-neutral pair trades to isolate platform optionality versus large pharma. Rotate modestly from defensive large-cap vaccine stocks into selective mRNA names as readouts de-risk; expect volatile 6–18 month windows around 2026 data. Entry: scale in now and add before early-2026 readouts; exit/trim on Phase IIb positive / Phase III start or if cash < $4.5B.

Contrarian angles: Market likely underprices rare-disease upside—successful registrational readouts in 2026 could re-rate valuations substantially given orphan pricing; conversely, consensus underestimates execution complexity of simultaneous multiple launches by 2028. Historical parallel: platform re-ratings (e.g., BNTX post-COVID) show fast rebounds on clinical validation but steep drawdowns on commercial misexecution. Unintended consequence: accelerated launches without supply resilience could force discounting and erode the projected 10% margin improvement.

Key Decisions for Investors

• Establish a 2–3% long position in MRNA (by portfolio weight) staged: 50% now, 50% ahead of the Phase IIb melanoma readout (early 2026). Use a 25% stop-loss; target 40–60% upside within 12–24 months if readouts/launch cadence progress as guided.
• Hedge the long with protective puts: buy 9–12 month MRNA puts ~30% OTM sized to cover 50% of the equity position (limits downside during readouts) and sell shorter-dated calls (covered) to finance premiums if willing to cap upside near +50%.
• Implement a dollar-neutral pair trade: long MRNA vs short PFE (equal notional) to express mRNA platform outperformance through 2026 catalysts; trim the pair if MRNA achieves Phase III start or if PFE announces material competing product uptake within 6–12 months.
• Buy long-dated, low-cost upside: small (0.5–1% notional) Jan 2028 call spread on MRNA (e.g., buy $40 call / sell $80 call) to capture multi-year pipeline value if rare-disease and multiple vaccine approvals materialize by 2028.
• Reduce 1–2% exposure to incumbent vaccine majors (SNY, GSK) and redeploy into select mRNA/biotech exposure; re-evaluate if Moderna cash falls below $4.5B or if management signals additional debt/equity financing within 60 days.